Esthesioneuroblastoma - A clinicopathologic study and role of DNA topoisomerase alpha

Suash Sharma, Mehar C. Sharma, Maribeth H Johnson, Mimi Lou, Alok Thakar, Chitra Sarkar

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Esthesioneuroblastoma (ENB) differs from adrenal neuroblastomas in its histopathologic and biologic characteristics. Hyams grading and Kadish staging have shown correlation with survival. Scant data are available on proliferation indices and prognosis. We retrospectively reviewed the clinicopathologic characteristics of ENB. Both Kadish and UCLA staging systems were used. Hyams grading was simplified into low and high grade. DNA topoisomerase II alpha labeling index (T2α LI) was obtained in 8 cases using immunohistochemistry. Of the 19 cases studied, 14 were males and 5 females. Age range was 2 to 62 years (average 27 years). The mass primarily involved the nose in 12 (63%) and paranasal sinuses in 7 cases (37%). Patients presented with nose block in 19 (100%), epistaxis in 10 (53%), proptosis in 9 (47%) and loss of vision in 6 cases (32%). Bony involvement was seen in 7 cases (37%), and intracranial spread in one case (5%). Thirteen (68%) were low-grade tumors and 6 were (32%) high-grade. There was no statistically significant difference between the low- and high-grade ENB in age (years) (p=0.2882), duration of symptoms (months) (p=0.5636), and either in the Kadish (p=0.5456) or the UCLA staging system (p=0.7771). The difference in DNA topoisomerase alpha labeling index between the low- and high-grade ENB (medians: 10.4 and 22.3, respectively) was not statistically significant (p=0.0714), but it was suggestive of a positive association. The results of this study should be interpreted with caution, because of the limited sample size. Three cases recurred locally, one each stage A, B and C, but all low-grade. This preliminary study suggests the need to combine a simplified histologic grading with accurate staging in a reasonable attempt to assess local progression in esthesioneuroblastoma. Larger studies may clarify the role of T2α LI in improving histologic grading.

Original languageEnglish (US)
Pages (from-to)123-129
Number of pages7
JournalPathology and Oncology Research
Volume13
Issue number2
DOIs
StatePublished - Jan 1 2007

Fingerprint

Olfactory Esthesioneuroblastoma
Type I DNA Topoisomerase
Nose
Epistaxis
Exophthalmos
Paranasal Sinuses
Neuroblastoma
Sample Size
Immunohistochemistry
Survival
Neoplasms

Keywords

  • Esthesioneuroblastoma
  • Topoisomerase alpha

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Esthesioneuroblastoma - A clinicopathologic study and role of DNA topoisomerase alpha. / Sharma, Suash; Sharma, Mehar C.; Johnson, Maribeth H; Lou, Mimi; Thakar, Alok; Sarkar, Chitra.

In: Pathology and Oncology Research, Vol. 13, No. 2, 01.01.2007, p. 123-129.

Research output: Contribution to journalReview article

Sharma, Suash ; Sharma, Mehar C. ; Johnson, Maribeth H ; Lou, Mimi ; Thakar, Alok ; Sarkar, Chitra. / Esthesioneuroblastoma - A clinicopathologic study and role of DNA topoisomerase alpha. In: Pathology and Oncology Research. 2007 ; Vol. 13, No. 2. pp. 123-129.
@article{ed4b4c150b334ecea62a6de5f2f8ccf3,
title = "Esthesioneuroblastoma - A clinicopathologic study and role of DNA topoisomerase alpha",
abstract = "Esthesioneuroblastoma (ENB) differs from adrenal neuroblastomas in its histopathologic and biologic characteristics. Hyams grading and Kadish staging have shown correlation with survival. Scant data are available on proliferation indices and prognosis. We retrospectively reviewed the clinicopathologic characteristics of ENB. Both Kadish and UCLA staging systems were used. Hyams grading was simplified into low and high grade. DNA topoisomerase II alpha labeling index (T2α LI) was obtained in 8 cases using immunohistochemistry. Of the 19 cases studied, 14 were males and 5 females. Age range was 2 to 62 years (average 27 years). The mass primarily involved the nose in 12 (63{\%}) and paranasal sinuses in 7 cases (37{\%}). Patients presented with nose block in 19 (100{\%}), epistaxis in 10 (53{\%}), proptosis in 9 (47{\%}) and loss of vision in 6 cases (32{\%}). Bony involvement was seen in 7 cases (37{\%}), and intracranial spread in one case (5{\%}). Thirteen (68{\%}) were low-grade tumors and 6 were (32{\%}) high-grade. There was no statistically significant difference between the low- and high-grade ENB in age (years) (p=0.2882), duration of symptoms (months) (p=0.5636), and either in the Kadish (p=0.5456) or the UCLA staging system (p=0.7771). The difference in DNA topoisomerase alpha labeling index between the low- and high-grade ENB (medians: 10.4 and 22.3, respectively) was not statistically significant (p=0.0714), but it was suggestive of a positive association. The results of this study should be interpreted with caution, because of the limited sample size. Three cases recurred locally, one each stage A, B and C, but all low-grade. This preliminary study suggests the need to combine a simplified histologic grading with accurate staging in a reasonable attempt to assess local progression in esthesioneuroblastoma. Larger studies may clarify the role of T2α LI in improving histologic grading.",
keywords = "Esthesioneuroblastoma, Topoisomerase alpha",
author = "Suash Sharma and Sharma, {Mehar C.} and Johnson, {Maribeth H} and Mimi Lou and Alok Thakar and Chitra Sarkar",
year = "2007",
month = "1",
day = "1",
doi = "10.1007/BF02893487",
language = "English (US)",
volume = "13",
pages = "123--129",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Esthesioneuroblastoma - A clinicopathologic study and role of DNA topoisomerase alpha

AU - Sharma, Suash

AU - Sharma, Mehar C.

AU - Johnson, Maribeth H

AU - Lou, Mimi

AU - Thakar, Alok

AU - Sarkar, Chitra

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Esthesioneuroblastoma (ENB) differs from adrenal neuroblastomas in its histopathologic and biologic characteristics. Hyams grading and Kadish staging have shown correlation with survival. Scant data are available on proliferation indices and prognosis. We retrospectively reviewed the clinicopathologic characteristics of ENB. Both Kadish and UCLA staging systems were used. Hyams grading was simplified into low and high grade. DNA topoisomerase II alpha labeling index (T2α LI) was obtained in 8 cases using immunohistochemistry. Of the 19 cases studied, 14 were males and 5 females. Age range was 2 to 62 years (average 27 years). The mass primarily involved the nose in 12 (63%) and paranasal sinuses in 7 cases (37%). Patients presented with nose block in 19 (100%), epistaxis in 10 (53%), proptosis in 9 (47%) and loss of vision in 6 cases (32%). Bony involvement was seen in 7 cases (37%), and intracranial spread in one case (5%). Thirteen (68%) were low-grade tumors and 6 were (32%) high-grade. There was no statistically significant difference between the low- and high-grade ENB in age (years) (p=0.2882), duration of symptoms (months) (p=0.5636), and either in the Kadish (p=0.5456) or the UCLA staging system (p=0.7771). The difference in DNA topoisomerase alpha labeling index between the low- and high-grade ENB (medians: 10.4 and 22.3, respectively) was not statistically significant (p=0.0714), but it was suggestive of a positive association. The results of this study should be interpreted with caution, because of the limited sample size. Three cases recurred locally, one each stage A, B and C, but all low-grade. This preliminary study suggests the need to combine a simplified histologic grading with accurate staging in a reasonable attempt to assess local progression in esthesioneuroblastoma. Larger studies may clarify the role of T2α LI in improving histologic grading.

AB - Esthesioneuroblastoma (ENB) differs from adrenal neuroblastomas in its histopathologic and biologic characteristics. Hyams grading and Kadish staging have shown correlation with survival. Scant data are available on proliferation indices and prognosis. We retrospectively reviewed the clinicopathologic characteristics of ENB. Both Kadish and UCLA staging systems were used. Hyams grading was simplified into low and high grade. DNA topoisomerase II alpha labeling index (T2α LI) was obtained in 8 cases using immunohistochemistry. Of the 19 cases studied, 14 were males and 5 females. Age range was 2 to 62 years (average 27 years). The mass primarily involved the nose in 12 (63%) and paranasal sinuses in 7 cases (37%). Patients presented with nose block in 19 (100%), epistaxis in 10 (53%), proptosis in 9 (47%) and loss of vision in 6 cases (32%). Bony involvement was seen in 7 cases (37%), and intracranial spread in one case (5%). Thirteen (68%) were low-grade tumors and 6 were (32%) high-grade. There was no statistically significant difference between the low- and high-grade ENB in age (years) (p=0.2882), duration of symptoms (months) (p=0.5636), and either in the Kadish (p=0.5456) or the UCLA staging system (p=0.7771). The difference in DNA topoisomerase alpha labeling index between the low- and high-grade ENB (medians: 10.4 and 22.3, respectively) was not statistically significant (p=0.0714), but it was suggestive of a positive association. The results of this study should be interpreted with caution, because of the limited sample size. Three cases recurred locally, one each stage A, B and C, but all low-grade. This preliminary study suggests the need to combine a simplified histologic grading with accurate staging in a reasonable attempt to assess local progression in esthesioneuroblastoma. Larger studies may clarify the role of T2α LI in improving histologic grading.

KW - Esthesioneuroblastoma

KW - Topoisomerase alpha

UR - http://www.scopus.com/inward/record.url?scp=34547636679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547636679&partnerID=8YFLogxK

U2 - 10.1007/BF02893487

DO - 10.1007/BF02893487

M3 - Review article

C2 - 17607373

AN - SCOPUS:34547636679

VL - 13

SP - 123

EP - 129

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 2

ER -